1. Market Research
  2. > Gram-Negative Bacterial Infections – Pipeline Review, H1 2013

Gram-Negative Bacterial Infections – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 228 pages

Gram-Negative Bacterial Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Gram-Negative Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gram-Negative Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Negative Bacterial Infections. Gram-Negative Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gram-Negative Bacterial Infections.
- A review of the Gram-Negative Bacterial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gram-Negative Bacterial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gram-Negative Bacterial Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gram-Negative Bacterial Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Gram-Negative Bacterial Infections - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gram-Negative Bacterial Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Gram-Negative Bacterial Infections 11
Gram-Negative Bacterial Infections Therapeutics under Development by Companies 13
Gram-Negative Bacterial Infections Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Gram-Negative Bacterial Infections Therapeutics - Products under Development by Companies 24
Gram-Negative Bacterial Infections Therapeutics - Products under Investigation by Universities/Institutes 30
Companies Involved in Gram-Negative Bacterial Infections Therapeutics Development 31
Baxter International Inc. 31
Shionogi and Co., Ltd. 32
Sanofi-Aventis 33
AstraZeneca PLC 34
GlaxoSmithKline plc 35
Nektar Therapeutics 36
Targeted Genetics Corporation 37
Merck and Co., Inc. 38
Dainippon Sumitomo Pharma Co., Ltd. 39
Takeda Pharmaceutical Company Limited 40
Nanotherapeutics, Inc. 41
Biological E. Limited 42
Rib-X Pharmaceuticals, Inc. 43
Novartis AG 44
Cubist Pharmaceuticals, Inc. 45
Pfizer Inc. 46
Wockhardt Limited 47
Zosano Pharma, Inc. 48
Intercell AG 49
Basilea Pharmaceutica Ltd. 50
Orchid Chemicals and Pharmaceuticals Ltd 51
Green Cross Corporation 52
LG Life Sciences, Ltd 53
Panacea Biotec Limited 54
PolyMedix, Inc. 55
Achaogen Inc. 56
Bharat Biotech International Limited 57
Shantha Biotechnics Limited 58
Novabiotics Ltd 59
ConjuGon, Inc. 60
Anacor Pharmaceuticals, Inc. 61
AiCuris GmbH and Co. KG 62
Destiny Pharma Ltd. 63
Viral Genetics, Inc. 64
NanoBio Corporation 65
Adeona Pharmaceuticals, Inc. 66
Trius Therapeutics, Inc. 67
Tetraphase Pharmaceuticals Inc. 68
TaiGen Biotechnology Co., Ltd. 69
Phico Therapeutics Ltd. 70
SelectX Pharmaceuticals, Inc. 71
Spider Biotech S.r.l. 72
PepTx, Inc. 73
Trana Discovery, Inc. 74
Cantab Biopharmaceuticals Limited 75
Indian Immunologicals Limited 76
Gram-Negative Bacterial Infections - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 83
ACHN-975 - Drug Profile 83
GelVac - Drug Profile 84
BAL-30072 - Drug Profile 85
RX-04 - Drug Profile 86
IC-15 - Drug Profile 87
WCK-771 - Drug Profile 88
Isac - Drug Profile 89
AN-3365 - Drug Profile 90
TP-2758 - Drug Profile 92
Act-HIB reconstituted with TRIPACEL - Drug Profile 93
avarofloxacin - Drug Profile 94
ceftobiprole medocaril - Drug Profile 96
(ceftazidime + avibactam) - Drug Profile 98
GyrB/ParE Program - Drug Profile 100
levonadifloxacin - Drug Profile 101
M-10ZH09 - Drug Profile 102
GSK-217744 - Drug Profile 104
DTP-HepB-Polio-Hib - Drug Profile 105
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 107
DTaP-HepB - Drug Profile 108
DtwP-HB-Hib (liq) Vaccine - Drug Profile 109
LBVF-0101 - Drug Profile 110
DTwP-HepB Vaccine - Drug Profile 111
SLP-0907 - Drug Profile 112
SLP-0901 - Drug Profile 113
FB-1811 - Drug Profile 114
BAC Gram -/+ - Drug Profile 115
SASPject PT3.X - Drug Profile 116
Easysix - Drug Profile 117
TAK-361S - Drug Profile 119
Typhoid TT Vaccine - Drug Profile 120
RX-05 - Drug Profile 121
OCID-5090 - Drug Profile 122
VGV-L - Drug Profile 123
Quadracel - Drug Profile 124
RX-P792 - Drug Profile 125
RX-P770 - Drug Profile 127
Gram-Negative Programme - Drug Profile 129
S-649266 - Drug Profile 130
Novarifyn - Drug Profile 131
PTX-002 - Drug Profile 132
MurB Program - Drug Profile 133
Lyme Disease Vaccine - Drug Profile 134
SB-056 - Drug Profile 135
Snare Antibacterial For Gram Negative Infections - Drug Profile 136
Vi-CRM197 PCMV - Drug Profile 137
B-4474 - Drug Profile 138
CB-027 - Drug Profile 139
(biapenem + RPX-7009) - Drug Profile 140
KPI-10 - Drug Profile 141
NB-401 - Drug Profile 142
MK-7655 - Drug Profile 143
3-(4-chlorophenyl)-4-Substituted Pyrazole Derivatives - Drug Profile 145
Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 146
MVX-506 - Drug Profile 147
Next Generation Inhaled Aminoglycoside Antibiotic - Drug Profile 148
SXP-2554 - Drug Profile 149
SXP-2523 - Drug Profile 150
Infectious Disease Program - Drug Profile 151
AbMGB - Drug Profile 152
XF-70 - Drug Profile 153
SM-295291 - Drug Profile 154
NAB-739 - Drug Profile 155
SM-369926 - Drug Profile 156
Vi-Diptheria Toxoid Conjugate Typhoid Vaccine - Drug Profile 157
Bivalent Enteric Fever Conjugate Vaccine - Drug Profile 158
Vi-PspA Conjugate Vaccine - Drug Profile 159
OmpC-Vi Conjugate Vaccine - Drug Profile 160
Multicomponent Lyme Vaccine - Drug Profile 161
Arenicin Program - Drug Profile 162
Typhetec - Drug Profile 163
SYN-005 - Drug Profile 164
Acellular Pertussis Vaccine - Drug Profile 165
DTwP-HBV-HIB Vaccine - Drug Profile 166
Thiolactomycin Analogues - Drug Profile 167
Pertussis Vaccine - Drug Profile 168
Prophenin - Drug Profile 169
Peptide Antibiotic - Drug Profile 170
Scrub Typhus Vaccine - Drug Profile 171
Bacterial Metallo Beta Lactamases Inhibitors - Drug Profile 172
Drug For Infectious Diseases - Drug Profile 173
Drug 1 For Gram-Negative Bacterial Infections - Drug Profile 174
Drug 2 For Gram-Negative Bacterial Infections - Drug Profile 175
PMX-633 - Drug Profile 176
PMX-668 - Drug Profile 177
PMX-693 - Drug Profile 178
Dap-3 Polymyxin Analogs - Drug Profile 179
GC-3111A - Drug Profile 180
Broad-Spectrum Antibiotics Targeting RNA-Exit-Channel - Drug Profile 181
VT-04 - Drug Profile 182
VT-01 - Drug Profile 183
S-200 Program - Drug Profile 184
NOSO-95 - Drug Profile 185
NOSO-74 - Drug Profile 186
doxycycline Nanosphere - Drug Profile 187
Acellular Pertussis Vaccine - Drug Profile 188
BioPhage-PA - Drug Profile 189
LBVP-0101 - Drug Profile 190
Anti-Gram Negative Bacteria Drug - Drug Profile 191
Antimicrobial Compounds Program - Drug Profile 192
Drug 3 For Gram-Negative Bacterial Infections - Drug Profile 193
Gram-Negative Bacterial Infections Therapeutics - Drug Profile Updates 194
Gram-Negative Bacterial Infections Therapeutics - Discontinued Products 207
Gram-Negative Bacterial Infections Therapeutics - Dormant Products 208
Gram-Negative Bacterial Infections - Product Development Milestones 213
Featured News and Press Releases 213
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 221
Disclaimer 221

List of Tables

Number of Products Under Development for Gram-Negative Bacterial Infections, H1 2013 18
Products under Development for Gram-Negative Bacterial Infections - Comparative Analysis, H1 2013 19
Number of Products under Development by Companies, H1 2013 21
Number of Products under Development by Companies, H1 2013 (Contd..1) 22
Number of Products under Development by Companies, H1 2013 (Contd..2) 23
Number of Products under Development by Companies, H1 2013 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2013 26
Comparative Analysis by Late Stage Development, H1 2013 27
Comparative Analysis by Mid Clinical Stage Development, H1 2013 28
Comparative Analysis by Early Clinical Stage Development, H1 2013 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 30
Products under Development by Companies, H1 2013 31
Products under Development by Companies, H1 2013 (Contd..1) 32
Products under Development by Companies, H1 2013 (Contd..2) 33
Products under Development by Companies, H1 2013 (Contd..3) 34
Products under Development by Companies, H1 2013 (Contd..4) 35
Products under Development by Companies, H1 2013 (Contd..5) 36
Products under Investigation by Universities/Institutes, H1 2013 37
Shionogi and Co., Ltd., H1 2013 39
Sanofi-Aventis, H1 2013 40
AstraZeneca PLC, H1 2013 41
GlaxoSmithKline plc, H1 2013 42
Nektar Therapeutics, H1 2013 43
Targeted Genetics Corporation, H1 2013 44
Merck and Co., Inc., H1 2013 45
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 46
Takeda Pharmaceutical Company Limited, H1 2013 47
Nanotherapeutics, Inc., H1 2013 48
Biological E. Limited, H1 2013 49
Rib-X Pharmaceuticals, Inc., H1 2013 50
Novartis AG, H1 2013 51
Cubist Pharmaceuticals, Inc., H1 2013 52
Pfizer Inc., H1 2013 53
Wockhardt Limited, H1 2013 54
Zosano Pharma, Inc., H1 2013 55
Intercell AG, H1 2013 56
Basilea Pharmaceutica Ltd., H1 2013 57
Orchid Chemicals and Pharmaceuticals Ltd, H1 2013 58
Green Cross Corporation, H1 2013 59
LG Life Sciences, Ltd, H1 2013 60
Panacea Biotec Limited, H1 2013 61
PolyMedix, Inc., H1 2013 62
Achaogen Inc., H1 2013 63
Bharat Biotech International Limited, H1 2013 64
Shantha Biotechnics Limited, H1 2013 65
Novabiotics Ltd, H1 2013 66
ConjuGon, Inc., H1 2013 67
Anacor Pharmaceuticals, Inc., H1 2013 68
AiCuris GmbH and Co. KG, H1 2013 69
Destiny Pharma Ltd., H1 2013 70
Viral Genetics, Inc., H1 2013 71
NanoBio Corporation, H1 2013 72
Adeona Pharmaceuticals, Inc., H1 2013 73
Trius Therapeutics, Inc., H1 2013 74
Tetraphase Pharmaceuticals Inc., H1 2013 75
TaiGen Biotechnology Co., Ltd., H1 2013 76
Phico Therapeutics Ltd., H1 2013 77
SelectX Pharmaceuticals, Inc., H1 2013 78
Spider Biotech S.r.l., H1 2013 79
PepTx, Inc., H1 2013 80
Trana Discovery, Inc., H1 2013 81
Cantab Biopharmaceuticals Limited, H1 2013 82
Assessment by Monotherapy Products, H1 2013 84
Assessment by Combination Products, H1 2013 85
Assessment by Stage and Route of Administration, H1 2013 87
Assessment by Stage and Molecule Type, H1 2013 89
Gram-Negative Bacterial Infections Therapeutics - Drug Profile Updates 201
Gram-Negative Bacterial Infections Therapeutics - Discontinued Products 214
Gram-Negative Bacterial Infections Therapeutics - Dormant Products 215
Gram-Negative Bacterial Infections Therapeutics - Dormant Products (Contd..1) 216
Gram-Negative Bacterial Infections Therapeutics - Dormant Products (Contd..2) 217
Gram-Negative Bacterial Infections Therapeutics - Dormant Products (Contd..3) 218
Gram-Negative Bacterial Infections Therapeutics - Dormant Products (Contd..4) 219

List of Figures

Number of Products under Development for Gram-Negative Bacterial Infections, H1 2013 18
Products under Development for Gram-Negative Bacterial Infections - Comparative Analysis, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 25
Late Stage Products, H1 2013 27
Mid Clinical Stage Products, H1 2013 28
Early Clinical Stage Products, H1 2013 29
Discovery and Pre-Clinical Stage Products, H1 2013 30
Assessment by Monotherapy Products, H1 2013 84
Assessment by Combination Products, H1 2013 85
Assessment by Route of Administration, H1 2013 86
Assessment by Stage and Route of Administration, H1 2013 87
Assessment by Molecule Type, H1 2013 88
Assessment by Stage and Molecule Type, H1 2013 89

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.